Table 4 Frequencies of chromosomal aberrations (CAs) induced by penoxsulam and the protective role of BBE.
Group I | Group II | Group II | Group IV | Group V | Group VI | |
|---|---|---|---|---|---|---|
SC | 0.60 ± 0.84 | 0.10 ± 0.32 | 0.00 ± 0.00 | 73.70 ± 8.72 | 57.60 ± 5.15 | 44.30 ± 6.36 |
FRG | 0.10 ± 0.32 | 0.00 ± 0.00 | 0.00 ± 0.00 | 69.10 ± 5.92 | 55.90 ± 3.93 | 43.90 ± 6.06 |
UDC | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 58.30 ± 5.31 | 43.50 ± 4.50 | 29.30 ± 4.88 |
B | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 44.90 ± 8.28 | 31.30 ± 6.27 | 20.70 ± 3.95 |
VC | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 34.50 ± 3.63 | 25.30 ± 5.77 | 18.90 ± 4.20 |
CM | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 25.80 ± 3.94 | 18.10 ± 4.04 | 15.40 ± 3.75 |
Total CAs | 0.70 ± 0.82d | 0.10 ± 0.32d | 0.00 ± 0.00d | 306.30 ± 32.88a | 231.70 ± 26.51b | 172.50 ± 17.04c |
CAs (%) | 0.07 | 0.01 | 0 | 30.63 ± 3.29a | 23.17 ± 2.65b | 17.25 ± 1.70c |
Mutagenicity inhibition(%) | – | – | – | – | 24.41 ± 5.10b | 43.78 ± 8.30a |